Marcia Brose, MD, PhD, lead investigator of Phase 3 Trial of Nexavar In Patients With Non-Responsive Thyroid Cancer

October 27, 2009

zikkir Health News

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer. This Phase 3 trial was started based on the results from Phase 2 clinical trials evaluating Nexavar in patients with advanced thyroid cancer.

“Patients with thyroid cancer who failed to respond to surgical or radiotherapies, have limited treatment options to help them manage their disease,” said Dimitris Voliotis, vice president,Nexavar clinical development, Bayer HealthCare Pharmaceuticals. “Recognizing this unmet need, we are evaluating Nexavar in this special patient population.” Read More